Date Title Description PDF
03 Nov 2021 On buy-back programmes The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. Download
16 Jul 2021 On Corporate Governance ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company   Download
22 Jun 2021 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. Download
22 Jun 2021 On significant placements in financial instruments Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. Download
29 Apr 2021 On business and financial situation The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States.     Download

Pages

Date Title Description PDF
11 May 2022 On Corporate Governance The Company informs about the appointment of a new member in its Board of Directors       Download
05 Apr 2022 Liquidity and counterparty agreements The Company communicates that it has entered into a liquidity agreement with Bestinver S.V., S.A.  Download
29 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted on 28 March 2022 and end of the share buyback program Download
28 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 21 March 2022 and 25 March 2022 Download
21 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 14 March 2022 and 18 March 2022 Download

Pages

Date Title Description PDF
06 Apr 2017 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the first quarter of 2017 Download
13 Mar 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to its biosimilar of Enoxaparin Download
07 Mar 2017 Otros sobre negocio y situación financiera ROVI informs that the Decentralised procedure used for the registration of its biosimilar of enoxaparin has been completed with positive outcome Download
16 Feb 2017 Otros sobre Gobierno Corporativo The Company informs about the agreements adopted by the Board of Directors Download
16 Feb 2017 Informe anual de remuneraciones de los consejeros ROVI releases the 2016 annual report regarding remuneration of the members of the Board of Directors Download

Pages